NEW DELHI: An expert panel from India’s central drug authority on Saturday recommended granting permission for emergency use of the Covid-19 vaccine developed in the country Covaxin under certain conditions, a day after giving a similar address for the Oxford Covid-19 vaccine, the sources said.
Covaxin has been developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
The Central Medicines Control Organization (CDSCO) Subject Matter Experts Committee (SEC) on Covid-19 again deliberated on Saturday on the Hyderabad-based pharmaceutical company emergency use authorization (USA) request after that presented additional data, facts and analysis after Friday’s review meeting, a source said.
Bharat Biotech had been applied to Drug controller General Of India (DCGI) requests emergency use authorization for its Covaxin on December 7.
On Friday, the SEC recommended granting permission for emergency restricted use of Oxford-AstraZeneca Covishield vaccine, manufactured by the Serum Institute of India.
.
